Focused On-demand Library for Protein SEC13 homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P55735

UPID:

SEC13_HUMAN

Alternative names:

GATOR complex protein SEC13; SEC13-like protein 1; SEC13-related protein

Alternative UPACC:

P55735; A8MV37; B4DXJ1; Q5BJF0; Q9BRM6; Q9BUG7

Background:

Protein SEC13 homolog, known as GATOR complex protein SEC13, plays a crucial role in cellular processes. It is a component of the nuclear pore complex (NPC) and the COPII coat, essential for the biogenesis of COPII-coated vesicles and the secretion of specific proteins from the endoplasmic reticulum. Additionally, as part of the GATOR2 subcomplex, it activates mTORC1 signaling, a key pathway in cell growth and metabolism, regulated by amino acid availability.

Therapeutic significance:

Understanding the role of Protein SEC13 homolog could open doors to potential therapeutic strategies. Its involvement in critical cellular pathways like mTORC1 signaling highlights its potential as a target in diseases where these pathways are dysregulated.